Summarized by Masters of Longevity from Longevity Technology.
ALSTARS enrollment update — a news article previewing trial progress and what readers can expect next, with context on timeline and study design.
Key Takeaways
- The ALSTARS trial reached planned enrollment of approximately 120 participants randomized across two COYA 302 dosing regimens and placebo.
- COYA 302 is an investigational combination of low-dose interleukin-2 and CTLA-4 Ig intended to enhance regulatory T cell function and suppress inflammation.
- Topline results from the 24-week double-blind treatment phase are expected in early Q2 2027.
